Navigation Links
Novavax Reports First Quarter 2009 Financial Results
Date:5/8/2009

expectations regarding revenues, operating expenses, cash burn, and clinical developments and anticipated milestones are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the Company's ability to progress any product candidates in preclinical or clinical trials; the scope, rate and progress of its preclinical studies and clinical trials and other research and development activities; clinical trial results; even if the data from preclinical studies or clinical trials is positive, the product may not prove to be safe and efficacious; Novavax's pilot plant facility is subject to extensive validation and FDA inspections, which may result in delays and increases costs; the effect or outcome of the Company's decision to sell Estrasorb(R); the human capital and other costs Novavax will incur to exit the manufacturing facility; our ability to enter into future collaborations with industry partners and the terms, timing and success of any such collaboration; the cost of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; our ability to obtain rights to technology; competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility; our ability to obtain adequate financing in the future through product licensing, co-promotional arrangements, public or private equity or debt financing or otherwise; general business conditions; competition; business abilities and judgment of personnel; and the availability of qualified personnel. Further information on the factors and risks that
'/>"/>
SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Novavax Announces Enrollment in the Second Phase II Study of its Seasonal Influenza VLP Vaccine Candidate
2. Novavax Announces Release Date of 2009 First Quarter, Financial Results and Investor Conference Call
3. Novavax Announces Early Retirement of $17 Million of Convertible Debt
4. NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains
5. Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India
6. Novavax Announces New Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
7. Novavax Announces Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
8. Novavax to Present at Cowen and Company 29th Annual Healthcare Conference
9. NOVAVAX Announces Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate Directed Against the Fusion (F) Protein
10. Novavax and Vivalis Sign a Research License Agreement to Use the EB66(R) Cell Line for the Production of Virus Like Particle Based Vaccines
11. Novavax Announces Operational Status of Its Vaccine Pilot Plant and Commercial Launch Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , January 15, 2014 A study ... races on the Formula 1 track could help to tackle ... Applied Technologies (MAT), Stowhealth (a GP surgery based in Stowmarket) ... healthcare provider Simplyhealth. Telemetry technology, which is inspired ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 DTS Language ... its Online Web Portal for Life Science organizations who need ... specify the subject matter of their documents in advance with ... help reduce time-to-delivery of translations, often a critical factor in ...
(Date:1/15/2014)... TaiGen Biotechnology Company, Limited ("TaiGen") today announced that ... leading Russian pharmaceutical company, to develop and commercialize nemonoxacin ... , Turkey and other ... novel antibiotic for the treatment of bacterial infections including ...
(Date:1/14/2014)... a leading provider of strategic communications services to corporations and organizations ... the United States and Europe ... is returning to the firm,s Washington, D.C. ... than two years of service as Associate Commissioner for the Office ...
Breaking Biology Technology:Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4DTS Improves Efficiency for Life Science Document Translations 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Former FDA Associate Commissioner Returns To 3D Communications 2
... WASHINGTON and WELLESLEY, Mass., July 29 Xceed,Molecular, ... analysis systems, will launch its new Inflammation Xpress,Chip, ... Ziplex automated,gene-expression analysis system, at the 2008 AACC/ASCLS ... opens today at Walter E. Washington,Convention Center in ...
... from the air we breathe and the food we eat ... or even beneficial, and only a handful pose any threat to ... , Research from the University of Wisconsin-Madison suggests the answer ... study appearing online this week in the Proceedings of the ...
... State and local officials have taken steps to ... major step for a cutting-edge technology that has yet ... On July 28, the Cambridge (Mass.) Public Health Department ... steps to gain a better understanding of the nature ...
Cached Biology Technology:Xceed Molecular to Launch New Inflammation Xpress Chip(TM)for the Ziplex(R) Automated Gene-Expression Analysis System at Clinical Lab Expo 2008, Booth 2155 2Xceed Molecular to Launch New Inflammation Xpress Chip(TM)for the Ziplex(R) Automated Gene-Expression Analysis System at Clinical Lab Expo 2008, Booth 2155 3Symbiotic microbes induce profound genetic changes in their hosts 2Local officials move toward monitoring nanotechnologies 2Local officials move toward monitoring nanotechnologies 3
(Date:4/17/2014)... bone marrow need to produce hydrogen sulfide in order ... a new study from the Center for Craniofacial Molecular ... USC. , Professor Songtao Shi, principal investigator on the ... the cells governs the flow of calcium ions. The ... results in osteogenesis, or the creation of new bone ...
(Date:4/17/2014)... This news release is available in German . ... fails to pay the protection money demanded of him, he ... are seldom required, however, as fear of the consequences is ... is observed in parasitic birds, which lay their eggs in ... egg out, the brood parasites take their revenge by destroying ...
(Date:4/17/2014)... novel method to help kidney stone sufferers ensure ... possible., Kidney stones represent a major medical problem ... untreated, apart from being particularly painful, they can ... many patients treated successfully, stone recurrence is also ... to diagnosis and treatment needs to be identified ...
Breaking Biology News(10 mins):Fear of the cuckoo mafia 2Fear of the cuckoo mafia 3
... 11 June 2009 - What dog owner has not come ... a guilty-looking dog slouching around the house? By ingeniously setting ... their dog had really committed an offense, Alexandra Horowitz, Assistant ... of the "guilty look" in dogs in the recently published ...
... why premature birth is a growing problem in the United ... that pre-pregnancy depressive mood appears to be a risk factor ... however, have nearly two times the odds of having a ... a University of Washington assistant professor of social work and ...
... Alcohol consumption by pregnant women hinders brain development ... processes that control thyroid hormone levels in the ... will be presented Wednesday at The Endocrine Society,s ... alcohol exposureeven from moderate drinking during pregnancycan cause ...
Cached Biology News:What really prompts the dog's 'guilty look' 2Pre-pregnancy depressed mood may heighten risk for premature birth 2Pre-pregnancy depressed mood may heighten risk for premature birth 3Specific genetic cause of fetal alcohol-related developmental disorders found 2
SHEEP ANTI HUMAN ESTRONE...
Request Info...
... culture systems provide an integrated ... for staining and imaging. Each ... preassembled with standard optical-quality coverslips ... entire system is provided sterile ...
... magnetic separator for 96-well microplates ... conjunction with the Captivate ferrofluid ... other magnetic particles and is ... Cell Biology Cell Separation Captivate ...
Biology Products: